Skip to content
Study details
Enrolling now

Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

SF Research Institute, Inc.
NCT IDNCT07220694ClinicalTrials.gov data as of Apr 2026
Target enrollment

140

Study length

about 28 days

Ages

40–80

Locations

1 site in CA

What this study is about

This trial is testing if a supplement called Sabroxy® can improve insulin resistance and thinking skills in adults with mild cognitive impairment and insulin resistance. Participants will take either Sabroxy® or a placebo for 8 weeks, and researchers will measure changes in insulin resistance, thinking skills, and other markers of health.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Sabroxy®

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Change in Inflammatory Biomarker (High-Sensitivity C-Reactive Protein, hs-CRP), Change in Montreal Cognitive Assessment (MoCA) Total Score

Body systems

Neurology